Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:March 1, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:March 1, 2024Recruiting
Condition(s):Advanced Solid TumorsLast Updated:March 6, 2020Completed
Condition(s):Germ Cell Tumor; Nonseminomatous Germ Cell Tumor; Seminoma; Germinomatous Germ Cell Tumor; Dysgerminoma; Pineal Germ Cell TumorLast Updated:May 6, 2023Active, not recruiting
Condition(s):MesotheliomaLast Updated:January 25, 2024Suspended
Condition(s):Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IV Breast CancerLast Updated:May 17, 2022Completed
Condition(s):Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7Last Updated:June 9, 2023Completed
Condition(s):Hepatocellular CarcinomaLast Updated:February 26, 2024Recruiting
Condition(s):Metastatic Breast CancerLast Updated:January 3, 2022Completed
Condition(s):Cutaneous MelanomaLast Updated:February 18, 2020Completed
Condition(s):Gastric Cancer; Microsatellite InstabilityLast Updated:October 31, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.